Product image of Olmesartan/Amlodipine Eg (Olmesartan Medoxomil, Amlodipine) supplied by GNH India

Olmesartan/Amlodipine Eg

Active Ingredient:
Olmesartan Medoxomil, Amlodipine
Origin:
EU

Olmesartan/Amlodipine Eg (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil / amlodipine, the active ingredient in Olmesartan/Amlodipine EG, is an angiotensin II receptor blocker combined with a calcium channel blocker presented as an oral tablet for systemic use. It is indicated for the management of hypertension in adult patients, offering complementary mechanisms to lower blood pressure.

GNH India supplies Olmesartan/Amlodipine EG as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets.

Manufacturer / TM Owner

Eurogenerics N.V./S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Olmesartan/Amlodipine is used in the cardiovascular therapeutic area to control elevated blood pressure.
  • Hypertension: lowers systolic and diastolic pressure in patients with primary hypertension.
  • Essential hypertension: provides additive blood‑pressure reduction when monotherapy does not achieve target levels.
  • Uncontrolled hypertension: employed as combination therapy to reach recommended blood‑pressure goals.

How It Works

  • Olmesartan medoxomil selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release. Amlodipine inhibits L‑type calcium channels in vascular smooth muscle, leading to arterial vasodilation. The combined effect reduces peripheral resistance and cardiac afterload, resulting in sustained blood‑pressure reduction.

Side Effects

Common Side Effects

  • Dizziness or light‑headedness
  • Headache
  • Peripheral edema, especially of the ankles
  • Flushing or warmth sensation
  • Fatigue or tiredness
  • Palpitations or mild tachycardia

Serious or Rare Side Effects

  • Angioedema involving face, lips or throat
  • Severe hypotension with syncope
  • Hepatic enzyme elevation or liver injury
  • Myocardial infarction or acute coronary syndrome
  • Life‑threatening arrhythmias
  • Severe allergic reactions such as Stevens‑Johnson syndrome

Precautions & Warnings

Olmesartan/Amlodipine should be used with clinical judgment and monitoring.

  • Pregnancy: Category D; avoid unless benefits outweigh risks.
  • Renal impairment: monitor kidney function and adjust therapy as needed.
  • Hepatic impairment: use cautiously; liver enzymes should be checked periodically.
  • Concomitant potassium‑sparing diuretics or supplements: risk of hyperkalemia; monitor serum potassium.
  • Severe aortic stenosis or cardiogenic shock: contraindicated due to risk of profound hypotension.
  • Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Olmesartan/Amlodipine may interact with several medicines that affect blood pressure or drug metabolism.

Major Interactions (Avoid)

  • Potassium‑sparing diuretics (e.g., spironolactone): increase risk of hyperkalemia.
  • Aliskiren in diabetic patients: heightened renal adverse events.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): raise amlodipine plasma levels.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect.
  • Lithium: elevated lithium concentrations and toxicity.

Moderate Interactions (Monitor Closely)

  • Rifampin or other CYP3A4 inducers: may reduce amlodipine exposure.
  • Carbamazepine: decreases amlodipine concentrations.
  • ACE inhibitors or other renin‑angiotensin system blockers: additive hypotensive effect.
  • Loop or thiazide diuretics: enhanced blood‑pressure lowering.
  • Beta‑blockers: potential for excessive bradycardia or hypotension.

Frequently Asked Questions

Olmesartan/Amlodipine EG is a fixed‑dose combination of an angiotensin II receptor blocker and a calcium‑channel blocker. It is prescribed to lower elevated blood pressure in adults with primary (essential) hypertension, often when a single agent does not achieve target levels.

Olmesartan medoxomil blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Amlodipine inhibits L‑type calcium channels in vascular smooth muscle, causing arterial dilation. Together they reduce peripheral resistance and cardiac afterload, producing a sustained antihypertensive effect.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s blood‑pressure profile, renal function, and concomitant therapies. The prescriber selects the appropriate strength and frequency according to clinical guidelines.

Olmesartan/Amlodipine EG is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless the potential benefit justifies the risk. Limited data are available for breastfeeding; the product should be used only if the potential benefit outweighs possible harm to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy, the combination offers dual mechanisms—AT1‑receptor blockade and calcium‑channel inhibition—resulting in greater blood‑pressure reduction and improved adherence due to a single tablet. It is often preferred over separate pills when tighter control is needed, but individual agents may be chosen based on patient‑specific factors such as comorbidities.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture, heat and direct sunlight. Do not use if the packaging is damaged or if tablets appear discolored.

Olmesartan/Amlodipine EG is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the prescriber’s instructions regarding timing and any dose adjustments.

Serious adverse events include angioedema, severe hypotension, hepatic injury, myocardial infarction, and life‑threatening arrhythmias. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, chest pain, or signs of liver dysfunction.

The combination is contraindicated in patients with known hypersensitivity to either component, severe aortic stenosis, cardiogenic shock, or those who are pregnant unless the benefit outweighs the risk. Caution is also advised for individuals with significant renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT